Spiko Closes $90M Series B, Signals Mid-Stage Investor Appetite

Spiko has closed a $90 million Series B funding round, according to a report from FinSMEs. The financing ranks among the larger Series B rounds reported this cycle and signals investor appetite at a stage where most companies raise meaningfully less.

How does the round size compare?

A $90 million Series B sits well above the median for the stage. Recent industry data put the median Series B round between $30 million and $50 million, putting Spiko's raise at roughly twice that benchmark.

Round sizes of this magnitude typically reflect one of three dynamics: a competitive process that drove the price up, a pre-emptive structure where existing investors led, or a deliberate decision by the company to take more capital than the round strictly required. In each case, the goal is the same — extend the runway and reduce the pressure of a quick Series C.

Series B capital is the bridge from product-market fit to scaled commercial growth. Companies at this stage burn cash on sales, marketing, regulatory build-out, and international expansion in pursuit of category leadership.

What details remain undisclosed?

The FinSMEs report does not name a lead investor, disclose participating funds, or provide a pre-money valuation. Use of proceeds, governance changes, and any board appointments tied to the financing are also absent from the initial coverage.

For a Series B of this size, those details usually matter more than the headline number. The lead investor often signals the round's strategic anchor — a growth-stage fund brings scaling expertise, a corporate strategic brings distribution, and a crossover fund signals expectations of a near-term public-market path.

Without that information, the round's intent remains interpretive.

What do typical Series B deal mechanics look like?

Series B preferred stock typically carries a 1x non-participating liquidation preference, broad-based weighted-average anti-dilution protection, and a drag-along clause that allows major investors to force a sale. Board composition generally expands to include one or two investor designees, and protective provisions usually cover new debt, acquisitions, and budget approvals above a defined threshold.

Investors at this stage price rounds on forward revenue multiples — typically 8x to 15x for high-growth businesses, though multiples have compressed meaningfully since the 2022 reset. Companies that can demonstrate gross margins above 70%, net dollar retention above 120%, and a clear path to default-alive status can still command premium structures even in a tougher market.

How does this fit the current market backdrop?

Spiko's round lands in a fundraising environment markedly different from the 2021 peak. Median Series B sizes have come down, term sheets include more covenants, and investors demand clearer evidence of unit economics.

Founders who would have raised on momentum in 2021 now face granular questions about customer acquisition cost payback periods, sales productivity, and burn multiples.

At the same time, capital is still flowing into the stage. Investors with conviction continue to underwrite multi-year journeys, and rounds of $50 million to $100 million remain achievable for companies with the metrics to support them.

What should readers watch next?

Several details will determine whether Spiko's $90 million reads as a benchmark transaction or an outlier once the full picture emerges:

• Lead investor identity and fund type
• Pre-money valuation and the implied revenue multiple
• Use of proceeds — geographic expansion, M&A, or product investment
• Board composition changes
• Any subsequent bridge financing or extension

Until those items surface, the round stands as one of the larger Series B transactions reported this cycle and a useful data point on where growth-stage investors are still willing to concentrate capital.